#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#
CS

Antiplatelet therapy for prevention of atherosclerosis in patients with diabetes

Czech version

Authors: Matej Samoš
Authors‘ workplace: I. interná klinika JLF UK a UNM, Martin
Published in: Forum Diab 2021; 10(Supplementum 1): 41-45
Category:

Overview

Type 2 diabetes mellitus (T2D) is a strong and independent risk factor of atherothrombotic vascular events. Recently, there are no doubts regarding the benefit of modern antiplatelet therapy in the secondary prevention of these events. However, the use of antiplatelets in primary prevention in patients with T2D remains controversial, as there is no clear evidence of its global benefit. This article reviews currently available data from clinical studies on the use of antiplatelet therapy in primary prevention of atherosclerosis and atherothrombosis in patients with T2D.

Keywords:

Antiplatelet therapy – Aspirin – Atherosclerosis – diabetes mellitus

Sources
  1. Samoš M, Fedor M, Kovář F et al. Type 2 Diabetes and ADP Receptor Blocker Therapy. J Diabetes Res 2016; 2016: 6760710. Dostupné z DOI: <http://dx.doi.org/10.1155/2016/6760710>.
  2. Bolek T, Samoš M, Staško J et al. Antitrombotická liečba v kardiológii: akútny koronárny syndróm, fibrilácia predsiení, venózna tromboembolická choroba a diabetes mellitus. P + M: Turany 2020. ISBN 978–80–89694–73–0.
  3. Bonaca MP, Bhatt DL, Cohen Met al. [PEGASUS-TIMI 54 Steering Committee and Investigators]. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med 2015; 372(19): 1791–1800. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa15008571800>.
  4. [ETDRS Investigators]. Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report 14. JAMA 1992; 268(10): 1292–1300. Dostupné z DOI: <http://dx.doi.org/10.1001/jama.1992.03490100090033>.
  5. de Gaetano G. [Collaborative Group of the Primary Prevention Project]. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Collaborative Group of the Primary Prevention Project. Lancet 2001; 357(9250): 89–95. Dostupné z DOI: <http://dx.doi.org/10.1016/s0140–6736(00)03539-x>.
  6. Sacco M, Pellegrini F, Roncaglioni MC et al. [PPP Collaborative Group]. Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial. Diabetes Care 2003; 26(12): 3264–3272. Dostupné z DOI: <http://dx.doi.org/10.2337/diacare.26.12.3264>.
  7. Gaede P, Vedel P, Larsen N et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348(5): 383–393. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa021778>.
  8. Calvin AD, Aggarwal NR, Murad MH et al. Aspirin for the primary prevention of cardiovascular events: a systematic review and meta-analysis comparing patients with and without diabetes. Diabetes Care 2009; 32(12): 2300–2306. Dostupné z DOI: <http://doi 10.2337/dc09–1297>.
  9. Leung WY, So WY, Stewart D et al. Lack of benefits for prevention of cardiovascular disease with aspirin therapy in type 2 diabetic patients – a longitudinal observational study. Cardiovasc Diabetol 2009; 8: 57. Dostupné z DOI: <http://dx.doi.org/10.1186/1475–2840–8-57>.
  10. Younis N, Williams S, Ammori B et al. Role of aspirin in the primary prevention of cardiovascular disease in diabetes mellitus: a meta-analysis. Expert Opin Pharmacother 2010; 11(9): 1459–1466. Dostupné z DOI: <http://dx.doi.org/10.1517/14656561003792538>.
  11. Sirois C, Moisan J, Poirier P et al. Myocardial infarction and gastro-intestinal bleeding risks associated with aspirin use among elderly individuals with type 2 diabetes. Ann Med 2014; 46(5): 335–340. Dostupné z DOI: <http://dx.doi.org/10.3109/07853890.2014.902636>.
  12. Bowman L, Mafham M, Wallendszus K et al. [ASCEND Study Collaborative Group]. Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus. N Engl J Med 2018; 379(16): 1529–1539. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1804988>.
  13. Saito Y, Okada S, Ogawa H et al. [JPAD Trial Investigators]. Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: 10-Year Follow-Up of a Randomized Controlled Trial. Circulation 2017; 135(7): 659–670. Dostupné z DOI: <http://dx.doi.org/10.1161/CIRCULATIONAHA.116.025760>.
  14. Caldeira D, Alves M, David C et al. Aspirin in the primary prevention of cardiovascular disease on diabetic patients: Systematic review and meta-analysis. Prim Care Diabetes 2020; 14(3): 213–221. Dostupné z DOI: <http://dx.doi.org/10.1016/j.pcd.2019.11.004>.
  15. Arnett DK, Blumenthal RS, Albert MA et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2019; 74(10): e177-e232. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacc.2019.03.010>.
  16. Cosentino F, Grant PJ, Aboyans V et al. [ESC Scientific Document Group]. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J 2020; 41(2): 255–323. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehz486>.
  17. Paven E, Dillinger JG, Bal Dit Sollier C et al. Determinants of aspirin resistance in patients with type 2 diabetes. Diabetes Metab 2020; 46(5): 370–376. Dostupné z DOI: <http://dx.doi.org/10.1016/j.diabet.2019.11.002>.
  18. Babel RA, Dandekar MP. A Review on Cellular and Molecular Mechanisms Linked to the Development of Diabetes Complications. Curr Diabetes Rev 2021; 17(4): 457–473. Dostupné z DOI: <http://dx.doi.org/10.2174/1573399816666201103143818>.
  19. Milionis H, Ntaios G, Papavasileiou V et al. Aspirin Versus Clopidogrel for Type 2 Diabetic Patients with First-Ever Noncardioembolic Acute Ischemic Stroke: Ten-Year Survival Data from the Athens Stroke Outcome Project. J Stroke Cerebrovasc Dis 2017; 26(12): 2769–2777. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jstrokecerebrovasdis.2017.06.052>.
  20. Lee WH, Chu CY, Hsu PC et al. Cilostazol for primary prevention of stroke in peripheral artery disease: a population-based longitudinal study in Taiwan. Thromb Res 2013; 132(2): 190–195. Dostupné z DOI: <http://dx.doi.org/10.1016/j.thromres.2013.01.036>.
Labels
Diabetology Endocrinology Internal medicine
Súčasné možnosti prevencie aterosklerózy pri diabete
Antidiabetic treatment in prevention of atherosclerosis: last decade
Hypolipidemic treatment in the prevention of atherosclerosis in diabetic patients
Antihypertensive treatment in the prevention of atherosclerosis in diabetic patients
Antidiabetic treatment in prevention of atherosclerosis: first half-century
Effect of antidiabetic treatment on incidence of stroke in patients with type 2. diabetes
Limitation and possible additive value of real world evidence in comparison with randomized clinical trials
Facts to remember: What is based on the evidence in atherosclerosis prevention in type 2 diabetes?
Article was published in

Forum Diabetologicum

Issue Supplementum 1
2021 Issue Supplementum 1
Download issue PDF
Most read in this issue
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#